biostudies-literatureUnknownNabizadeh F<h4>Background</h4>Previously, several studies investigated the effect of cladribine among patients with multiple sclerosis (MS) as a treatment option. Due to the contradictory results of previous studies regarding the efficacy and safety of cladribine in the MS population, we aimed to conduct a systematic review and meta-analysis by including clinical trials and observational studies in terms of having more confirmative results to make a general decision.<h4>Methods</h4>The three databases including PubMed, Scopus, and Web of Science were comprehensively searched in May 2022. We included the studies that investigated the efficacy and safety of cladribine in patients with MS. Eligible studies have to provide sufficient details on MS diagnosis and appropriate follow-up duration. We investigNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiologyhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC10106322biostudies-literatureSafety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.PMC10106322Afrashteh FNabizadeh FMirmosayyeb ORahmani SNajdaghi SRajabi RMohamadi MfalseSafety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.<h4>Background</h4>Previously, several studies investigated the effect of cladribine among patients with multiple sclerosis (MS) as a treatment option. Due to the contradictory results of previous studies regarding the efficacy and safety of cladribine in the MS population, we aimed to conduct a systematic review and meta-analysis by including clinical trials and observational studies in terms of having more confirmative results to make a general decision.<h4>Methods</h4>The three databases including PubMed, Scopus, and Web of Science were comprehensively searched in May 2022. We included the studies that investigated the efficacy and safety of cladribine in patients with MS. Eligible studies have to provide sufficient details on MS diagnosis and appropriate follow-up duration. We investig2023-01-01T00:00:00Z2023 Apr2025-04-18T15:00:31.265Z2025-04-07T01:26:49.795ZS-EPMC101063223706278710.1007/s10072-023-06794-w